Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
60,700.60 -995.63 (-1.61%) CMC Crypto 200
1,265.94 -17.89 (-1.39%)
PTCT Dec 2025 15.000 put
| Previous close | 1.7500 |
| Open | 1.6500 |
| Bid | 0.1000 |
| Ask | 2.9500 |
| Strike | 15.00 |
| Expiry date | 2025-12-19 |
| Day's range | 1.6500 - 1.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
PR NewswireCHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nmDMD. This opinion follows the return of the previously issued negative opinion by the European Commission (EC) for re-review.
ZacksPTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,380 shares of its common stock and 6,260 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to nine new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
